| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ... Journal of Clinical Oncology 36 (17), 1714-1768, 2018 | 3848 | 2018 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ... The Lancet 387 (10030), 1837-1846, 2016 | 2999 | 2016 |
| Sotorasib for Lung Cancers with KRAS p.G12C Mutation F Skoulidis, BT Li, GK Dy, TJ Price, GS Falchook, J Wolf, A Italiano, ... New England Journal of Medicine 384 (25), 2371-2381, 2021 | 1447 | 2021 |
| Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update BJ Schneider, J Naidoo, BD Santomasso, C Lacchetti, S Adkins, ... Journal of Clinical Oncology 39 (36), 4073-4126, 2021 | 1249 | 2021 |
| Multidisciplinary management of lung cancer A Spira, DS Ettinger New England Journal of Medicine 350 (4), 379-392, 2004 | 1222 | 2004 |
| First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations LV Sequist, RG Martins, D Spigel, SM Grunberg, A Spira, PA Janne, ... Journal of clinical oncology 26 (15), 2442-2449, 2008 | 1054 | 2008 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 968 | 2018 |
| Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. AI Spira, PA Marx, BK Patterson, J Mahoney, RA Koup, SM Wolinsky, ... The Journal of experimental medicine 183 (1), 215-225, 1996 | 894 | 1996 |
| Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized … GD Demetri, M Von Mehren, RL Jones, ML Hensley, SM Schuetze, ... Journal of Clinical Oncology 34 (8), 786-793, 2016 | 881 | 2016 |
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study SHI Ou, JS Ahn, L De Petris, R Govindan, JCH Yang, B Hughes, H Lena, ... Journal of clinical oncology 34 (7), 661-668, 2016 | 735 | 2016 |
| Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation PA Jänne, GJ Riely, SM Gadgeel, RS Heist, SHI Ou, JM Pacheco, ... New England Journal of Medicine 387 (2), 120-131, 2022 | 665 | 2022 |
| Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial C Butts, MA Socinski, PL Mitchell, N Thatcher, L Havel, M Krzakowski, ... The lancet oncology 15 (1), 59-68, 2014 | 578 | 2014 |
| Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ... Journal of Clinical Oncology 39 (30), 3391-3402, 2021 | 560 | 2021 |
| Progesterone implants enhance SIV vaginal transmission and early virus load PA Marx, AI Spira, A Gettie, PJ Dailey, RS Veazey, AA Lackner, ... Nature medicine 2 (10), 1084-1089, 1996 | 552 | 1996 |
| Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study AE Perl, JK Altman, J Cortes, C Smith, M Litzow, MR Baer, D Claxton, ... The Lancet Oncology 18 (8), 1061-1075, 2017 | 545 | 2017 |
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial DC Smith, MR Smith, C Sweeney, AA Elfiky, C Logothetis, PG Corn, ... Journal of clinical oncology 31 (4), 412-419, 2013 | 531 | 2013 |
| Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C R Yaeger, J Weiss, MS Pelster, AI Spira, M Barve, SHI Ou, TA Leal, ... New England Journal of Medicine 388 (1), 44-54, 2023 | 299 | 2023 |
| Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification B Bulik-Sullivan, J Busby, CD Palmer, MJ Davis, T Murphy, A Clark, ... Nature biotechnology 37 (1), 55-63, 2019 | 298 | 2019 |
| Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Thoracic Oncology 16 (12), 2091-2108, 2021 | 297 | 2021 |
| Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open … V Subbiah, J Wolf, B Konda, H Kang, A Spira, J Weiss, M Takeda, Y Ohe, ... The Lancet Oncology 23 (10), 1261-1273, 2022 | 284 | 2022 |
